~75%
of pre-clinical and clinical programs have
genetic support
A mix of
innovative molecules, potential
new indications, and biosimilars


A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.

Download Pipeline Chart

*   Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

   In addition to the above programs, AMJEVITA/AMGEVITA and MVASI have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). KANJINTI has been approved by the EC and we have refiled our BLA with the FDA. We are also pursuing other biosimilar product candidates in earlier-stage clinical development.

**   Tradename provisionally approved by the FDA.